{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Riou C"],"funding":["European & Developing Countries Clinical Trials Partnership (EDCTP)","NIAID NIH HHS","Wellcome Trust"],"pubmed_abstract":["<h4>Background</h4>We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.COV2.S, with 91.4% showing evidence of previous SARS-CoV-2 infection.<h4>Methods</h4>A total of 286 adults (with or without HIV) were enrolled >4 months after an Ad26.COV2.S prime and randomized 1:1:1:1 to receive either a full or half-dose booster of Ad26.COV2.S or BNT162b2 vaccine. B cell responses (binding, neutralization and antibody dependent cellular cytotoxicity-ADCC), and spike-specific T-cell responses were evaluated at baseline, 2, 12 and 24 weeks post-boost. Antibody and T-cell immunity targeting the Ad26 vector was also evaluated.<h4>Results</h4>No vaccine-associated seriou"],"journal":["medRxiv : the preprint server for health sciences"],"pagination":["2023.11.20.23298785"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10690356"],"repository":["biostudies-literature"],"pubmed_title":["Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants."],"pmcid":["PMC10690356"],"funding_grant_id":["75N93021C00016","96833","UM1 AI068614","TMA2016SF-1535","226137/Z/22/Z","75N93019C00065","TMA2017SF-1951"],"pubmed_authors":["Sette A","Moyo-Gwete T","Rees H","Riou C","Ayres F","Gill K","Ngomti A","Panchia R","Sigal A","Madzivhandila M","Patel F","Singh U","Benede N","Mosala P","Hermanus T","Balla SR","Grifoni A","Venter EM","Dhar M","Nesamari R","Besethi AS","Mkhize Q","Manamela NP","Garrett N","Nkayi AA","Bekker LG","Bernstein M","Walters A","Nana A","Kaldine H","Mzindle NB","Kgagudi P","Crowther C","Nkosi TP","Moore PL","Fairlie L","Makhado Z","Geyer S","Ganga Y","Bhiman JN","Motlou TP","Burgers WA","Keeton RS","Baguma R","Lazarus E","Omondi MA","van Graan S","Lustig G","Sawry S","Richardson SI","Roux JL","Magugu SF","Mutavhatsindi H","Gray G","Khan K","Cele S"],"additional_accession":[]},"is_claimable":false,"name":"Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.","description":"<h4>Background</h4>We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.COV2.S, with 91.4% showing evidence of previous SARS-CoV-2 infection.<h4>Methods</h4>A total of 286 adults (with or without HIV) were enrolled >4 months after an Ad26.COV2.S prime and randomized 1:1:1:1 to receive either a full or half-dose booster of Ad26.COV2.S or BNT162b2 vaccine. B cell responses (binding, neutralization and antibody dependent cellular cytotoxicity-ADCC), and spike-specific T-cell responses were evaluated at baseline, 2, 12 and 24 weeks post-boost. Antibody and T-cell immunity targeting the Ad26 vector was also evaluated.<h4>Results</h4>No vaccine-associated seriou","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2026-05-14T03:15:44.795Z","creation":"2025-04-05T11:15:17.504Z"},"accession":"S-EPMC10690356","cross_references":{"pubmed":["38045321"],"doi":["10.1101/2023.11.20.23298785"]}}